Back to search
FDAFDA · Food and drugs·Recall number D-0428-2024

Tri-Lo-Sprintec (norgestimate and ethinyl estradiol) tablets USP - triphasic regimen, packaged in carton containing 3 Blister Cards, 28 Tablets Each, Rx only, Teva Pharmaceuticals USA, INC, North Wales, PA 19454, NDC 0093-2140-62

Published April 3, 2024 · Recall initiated: March 7, 2024

Summary

FDA records drug Class II recall D-0428-2024, published April 3, 2024 and initiated March 7, 2024. Recalling firm: Teva Pharmaceuticals USA, Inc; Status: Terminated; Reported quantity: 92,676 cartons; Lot: Lot # 100039678, Exp 04/31/2024; 100038111, 100042277, Exp 07/31/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if TRI-LO-SPRINTEC has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TRI-LO-SPRINTEC
Manufacturer
Teva Pharmaceuticals USA, Inc
Distributor
USA nationwide.
Lot
Lot # 100039678, Exp 04/31/2024; 100038111, 100042277, Exp 07/31/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tri-Lo-Sprintec (norgestimate and ethinyl estradiol) tablets USP - triphasic regimen, packaged in carton containing 3 Blister Cards, 28 Tablets Each, Rx only, Teva Pharmaceuticals USA, INC, North Wales, PA 19454, NDC 0093-2140-62 recalled?

Yes. FDA published recall D-0428-2024 on April 3, 2024. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TRI-LO-SPRINTEC.